Data sourced dynamically from the Open Targets GraphQL API.
Clinical Records Found: 1137
Highest Clinical Phase: Phase 2
* Note on Association Scores: The Open Targets platform calculates this harmonic sum score (0.0 to 1.0) by aggregating evidence from genetics, somatic mutations, transcriptomics, drugs, animal models, and text-mining. A higher score indicates stronger multi-modal evidence linking the target (CD163) to the specific disease.
Whitespace Analysis: CD163 is a well-known marker of alternatively activated (M2) macrophages, which are heavily implicated in fibrotic and tumor-microenvironment immunosuppressive states. The presence of Phase 1/2 clinical activity indicates the industry is actively pursuing CD163-targeted therapeutics or antibody-drug conjugates (ADCs) to deplete these pathological macrophages. However, the relatively low volume of advanced trials suggests this is still an emerging, uncrowded therapeutic whitespace compared to classic checkpoints like PD-1.